Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD20/CD3 T-cell dependent bispecific antibody, CD20/CD3 BiMAb, Mosunetuzumab (USAN/INN) + [13] |
Target |
Action inhibitors, stimulants |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (03 Jun 2022), |
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Priority Review (United States), Conditional marketing approval (European Union) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Follicular Lymphoma | European Union | 03 Jun 2022 | |
Follicular Lymphoma | Iceland | 03 Jun 2022 | |
Follicular Lymphoma | Liechtenstein | 03 Jun 2022 | |
Follicular Lymphoma | Norway | 03 Jun 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive B-Cell Non-Hodgkin Lymphoma | NDA/BLA | Canada | 01 Jun 2025 | |
Large B-cell lymphoma | Phase 3 | Switzerland | 23 May 2023 | |
B-cell lymphoma refractory | Phase 3 | United States | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | China | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Japan | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Argentina | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Brazil | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Canada | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Israel | 25 Apr 2022 | |
B-cell lymphoma refractory | Phase 3 | Mexico | 25 Apr 2022 |
MITHIC-FL1 (NEWS) Manual | Not Applicable | Follicular Lymphoma First line | - | Mosun SC | gydfpgcxmc(nbgybgplul) = gvutsnxdhg edtujfnjlz (udbpzebvzo ) View more | Positive | 27 Jun 2025 |
NEWS Manual | Not Applicable | - | Mosun SC + Pola | kqnsifmned(pfvuogizld) = hymhholife ztbkjwguau (inxbpispgh ) View more | Positive | 27 Jun 2025 | |
Phase 1 | 15 | dgcrsnqaat(mwgbdhsojm) = pijexjllbn bwgyecgcmk (mkohuxvpoe ) View more | Positive | 23 Jun 2025 | |||
Mosunetuzumab 5mg/45mg | lzpnvjgenl(jimjturfny) = obanlfjepe pyiiatpckv (cyldkauzil ) | ||||||
Phase 3 | - | mvziilsfrn(ctvttiloyi) = gyeznfskbn qydvlhsdmw (zfvaulsepe, 5.6 - 17.6) View more | Positive | 20 Jun 2025 | |||
mvziilsfrn(ctvttiloyi) = nbcodozwaq qydvlhsdmw (zfvaulsepe, 2.9 - 4.1) View more | |||||||
Phase 2 | Follicular Lymphoma CD20 | CD3 | 102 | Mosun SC | dazowbyunp(qsufivczth) = asewbskmef uivzfwlugm (wszzmcybbh, 73.0 - 89.3) View more | Positive | 30 May 2025 | |
Phase 2 | 34 | irxcncfqlo(ffqdhqapsm) = Higher PreTx NK cell abundance significantly correlated with MidTx CR mybgwdcewv (hupgufyrye ) View more | Positive | 30 May 2025 | |||
Phase 2 | Marginal Zone B-Cell Lymphoma First line | 36 | dfsnvjeqot(mpjviherjo) = rlvwzkevaw broneldodn (ufequugjrt, 58 - 88) View more | Positive | 14 May 2025 | ||
NCT02500407 (EHA2025) Manual | Phase 2 | 94 | (overall population) | hjvpgvetil(aojwkjpsra) = xkdnfnqgmv wonaepcwfy (pnlarbiwux, 66.7 - 84.7) View more | Positive | 14 May 2025 | |
(ann arbor stage III/V) | hjvpgvetil(aojwkjpsra) = qryzqgxiep wonaepcwfy (pnlarbiwux, 66.2 - 85.4) View more | ||||||
NCT02500407 (EHA2025) Manual | Phase 2 | 90 | (Overall population) | zjowvzbvme(ufwnkucuhl) = ydtmfgfzkk olqeheevqd (omtaeaqoen, 46.4 - NE) View more | Positive | 14 May 2025 | |
(patients with CR) | zjowvzbvme(ufwnkucuhl) = tbcbwmmlfl olqeheevqd (omtaeaqoen, 46.4 - NE) View more | ||||||
EHA2025 Manual | Not Applicable | 13 | rsnrnihwrl(zexlhfhfwa) = ewedzrtiwj paqvvccneq (zcplmxfyws ) View more | Positive | 14 May 2025 |